Table 1. Summary of aggregate clinicopathological data for all patient samples included in the cross-validation.
| Parameter | % | N |
|---|---|---|
| Gender | ||
| Male | 53.1% | 566 |
| Female | 22.9% | 244 |
| No data | 23.9% | 255 |
| Systemic treatment | ||
| No Adjuvant | 36.9% | 393 |
| Adjuvant | 22.3% | 238 |
| No data | 40.8% | 434 |
| Histology (Lauren class.) | ||
| Diffuse | 23.3% | 248 |
| Intestinal | 31.5% | 336 |
| Mixed | 3.1% | 33 |
| No data | 42.1% | 448 |
| Differentiation | ||
| Poor | 15.6% | 166 |
| Moderate | 6.3% | 67 |
| Well | 3.0% | 32 |
| No data | 75.1% | 800 |
| pT | ||
| T1 | 1.3% | 14 |
| T2 | 23.8% | 253 |
| T3 | 19.5% | 208 |
| T4 | 3.7% | 39 |
| No data | 51.7% | 551 |
| pN | ||
| N0 | 7.1% | 76 |
| N1 | 21.8% | 232 |
| N2 | 12.1% | 129 |
| N3 | 7.1% | 76 |
| No data | 51.8% | 552 |
| cM | ||
| M0 | 43.1% | 459 |
| M1 | 5.4% | 58 |
| No data | 51.5% | 548 |
| AJCC Stage | ||
| I | 6.5% | 69 |
| II | 13.6% | 145 |
| III | 30.0% | 319 |
| IV | 14.3% | 152 |
| No data | 35.7% | 380 |